Capricor Therapeutics lost roughly two-thirds of its market value on Monday. Not from a failed trial. From a document explaining what a panel might discuss on Wednesday. Curis and Autonomix Medical had smaller, quieter reactions of their own to their own news this week, one up, one down, each worth understanding on its own terms.
Capricor Plunges Up to 67% After FDA Briefing Casts Doubt on Duchenne Cell Therapy
Capricor Therapeutics (Nasdaq: CAPR) shares fell as much as 67% on July 27, later paring the loss to around 63%. The trigger wasn’t a vote. It was a document. The FDA released its briefing materials ahead of a July 29 Cellular, Tissue, and Gene Therapies Advisory Committee meeting on the company’s Biologics License Application for deramiocel, a cell therapy for Duchenne muscular dystrophy-associated cardiomyopathy.
A negative CBER briefing document ahead of an advisory committee meeting is one of the more reliable predictors of how the vote itself goes. Capricor’s was about as negative as they get. Reviewers called the efficacy case comprehensively negative and concluded the drug’s benefit-risk profile appears unfavorable. They also flagged a lopsided rate of hypersensitivity reactions between treatment arms and raised the possibility that pattern had functionally unblinded parts of the trial. This is Capricor’s second attempt at winning approval for deramiocel.
CEO Linda Marban disputed the FDA’s reading the same day, arguing the agency’s post-hoc analyses leaned on an unsigned, incomplete internal draft of the statistical plan rather than the final version that actually governed the Phase 3 HOPE-3 trial. That final plan, per Capricor, produced a statistically significant result on the primary endpoint with supportive cardiac benefits. The company has not addressed the FDA’s specific unblinding concern point by point.
Wall Street split hard. B. Riley cut its rating to Neutral and slashed its price target from $63 to $10. Other desks, including Oppenheimer, kept Buy ratings through the drop. Capricor’s market cap sits near $420 million, down sharply from before Monday’s rout. Wednesday’s vote is advisory only, and the FDA can approve or reject deramiocel regardless of what the panel decides.
Curis Jumps 11% as Updated Lymphoma Data Support an Accelerated Approval Path
Small patient numbers can make a response rate look more dramatic than it is. Curis’s July 22 update leans on that dynamic and still delivers real signal. Shares of Curis, Inc. (Nasdaq: CRIS) climbed about 11% after the company released updated data from its TakeAim Lymphoma study evaluating emavusertib, an oral IRAK4 and FLT3 inhibitor, paired with ibrutinib for Primary CNS Lymphoma.
Among BTK-inhibitor-naive patients, the objective response rate reached 100% in five evaluable patients and 86% across all seven enrolled, up from 71% at the prior cutoff in May 2025. Patients who had already been on a BTK inhibitor fared worse, at 33% among 30 evaluable and 26% across all 39. Both numbers improved from the last update. According to Curis, regulators in the US and Europe have indicated the ongoing single-arm study could support a future accelerated approval filing for relapsed or refractory disease. That is a conditional could, not a commitment.
A related Phase 2 study combining emavusertib with zanubrutinib in chronic lymphocytic leukemia is moving too. Ten patients have consented, and the company now expects data from five to ten patients by December 2026, up from an earlier target of five. Emavusertib carries Orphan Drug Designation from the FDA for this lymphoma along with AML and MDS. Curis itself is a distressed name. It completed a 1-for-20 reverse split on July 6 after Nasdaq flagged the stock for trading below the $1 minimum bid price for 30 straight days.
Autonomix Medical Falls 16% on Preclinical Renal Denervation Data
Autonomix Medical (Nasdaq: AMIX) fell about 16% around July 26, despite announcing preclinical results the company itself framed as good news. The data covers its catheter-based neural sensing platform in renal denervation, a procedure used to treat resistant hypertension.
In an animal study, the device tracked neural activity at several points along the renal artery and picked up reduced signal levels after targeted ablation. The company notes that is the kind of direct physiological feedback current renal denervation procedures lack, since physicians today rely mostly on anatomical landmarks instead. None of this involved a human patient. Autonomix’s only clinical-stage program remains its pancreatic cancer pain candidate. A new US patent covering the neuromodulation platform followed on July 23.
A market that sells off news a company calls positive is usually pricing in something other than the science, and Autonomix’s share count tells that story on its own. The stock went through a 1-for-21 reverse split as recently as June, and its market cap sits in the low single digits of millions of dollars. Heavy dilution through warrants and at-the-market offerings is part of its recent history, not a hypothetical risk.
CAPR, CRIS, AMIX: What to Watch
No. It is a recommendation, not a decision. The FDA can approve or reject deramiocel either way, and its own ruling on the Biologics License Application comes later, on a separate timeline.
The company expects to dose its first five patients by the end of July 2026, with results from five to ten patients targeted for December.
Not for renal denervation specifically. The company has described a staged preclinical plan before any clinical study in this application, and its one active human trial remains focused on pancreatic cancer pain.
Sources
- Seeking Alpha: Capricor plunges on FDA AdCom briefing doc for Duchenne treatment, July 27, 2026
- GlobeNewswire: Capricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for Deramiocel, July 27, 2026
- PRNewswire / BioSpace: Curis Announces Positive Emavusertib Update, July 22, 2026
- GlobeNewswire / BioSpace: Autonomix Medical Demonstrates Renal Nerve Sensing and Neural Activity Change in Preclinical Study, July 24, 2026
Editorial Disclosure
This roundup is based entirely on publicly available information including named wire service releases, company press releases, and financial news reporting. Securities and entities discussed include Capricor Therapeutics, Inc. (Nasdaq: CAPR), Curis, Inc. (Nasdaq: CRIS), and Autonomix Medical, Inc. (Nasdaq: AMIX). aktiego.com has not received any compensation from any company, IR firm, or third party mentioned. No staff member or principal of aktiego.com holds a position in any security mentioned at the time of publication. Capricor’s stock decline and the contents of the FDA’s briefing document are sourced to the company’s own July 27, 2026 press release and contemporaneous financial reporting; the July 29, 2026 advisory committee vote is non-binding and the FDA’s ultimate decision on the Biologics License Application has not been made as of publication. Capricor’s characterization of the FDA’s analysis as relying on an outdated draft statistical plan is the company’s own stated position, not independently verified by aktiego.com or confirmed by the FDA. Capricor’s market capitalization is approximately $420 million as of publication; the stock’s single-day decline of up to 67% is a material risk factor investors should weigh independently. B. Riley’s rating downgrade and price target cut are sourced to Investing.com’s July 27, 2026 report and represent that firm’s opinion, not independently verified by aktiego.com. Curis’s clinical data is sourced to its July 22, 2026 press release; response rates cited are based on small evaluable patient populations (as few as five to seven patients in some subgroups) and have not been independently verified or peer-reviewed. Curis is a distressed nano-cap that completed a 1-for-20 reverse stock split on July 6, 2026 after receiving a Nasdaq delisting determination for a bid-price violation. Autonomix Medical’s preclinical data is sourced to its July 24, 2026 press release and reflects animal-model results only, with no human clinical data for this specific application; Autonomix is an extremely small, thinly traded nano-cap with a documented history of reverse stock splits and share dilution through warrant and at-the-market offerings. Small cap, micro-cap, and nano-cap stocks listed on the CSE, TSX, TSXV, and Nasdaq are speculative investments carrying significant risk including potential total loss of capital, and the volatility on display in this roundup, from a 67% single-day decline to a sell-off on preclinical data framed as positive, is representative of that risk. Coverage on aktiego.com is provided for informational and educational purposes only. aktiego.com is not a registered investment advisor. Nothing in this article constitutes financial, investment, or professional advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making any investment decisions. For more information please see our full DISCLAIMER
